Anti-Angiogenic Drugs: Involvement in Cutaneous Side Effects and Wound-Healing Complication.

about

Anti-Angiogenic Drugs: Involvement in Cutaneous Side Effects and Wound-Healing Complication.

Item

http://www.wikidata.org/entity/Q42926957

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Anti-Angiogenic Drugs: Involve ...... nd Wound-Healing Complication.

@en

Anti-Angiogenic Drugs: Involve ...... nd Wound-Healing Complication.

@nl

type

Item

label

Anti-Angiogenic Drugs: Involve ...... nd Wound-Healing Complication.

@en

Anti-Angiogenic Drugs: Involve ...... nd Wound-Healing Complication.

@nl

prefLabel

Anti-Angiogenic Drugs: Involve ...... nd Wound-Healing Complication.

@en

Anti-Angiogenic Drugs: Involve ...... nd Wound-Healing Complication.

@nl

P1476

Anti-Angiogenic Drugs: Involve ...... nd Wound-Healing Complication.

@en

P2093

Richard J Bodnar

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of the VEGF binding site on the Flt-1 receptor

The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis

Tumor angiogenesis: therapeutic implications

The biology of VEGF and its receptors

Vascular endothelial growth factor (VEGF) and its receptors

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Regulation of scar formation by vascular endothelial growth factor.

Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells.

P304

635-646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1089/WOUND.2013.0496

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25302138

http://www.w3.org/2001/XMLSchema#string

P932

4183909

http://www.w3.org/2001/XMLSchema#string